Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1157063 | 0.87 | KMT2A (0.48) | KMT2AALDH1A1MEN1HTTLMNA | |
| SCHEMBL1157054 | 0.85 | GAA (0.40) | ALDH1A1HTTLMNAGAANPSR1 | |
| SCHEMBL1156711 | 0.85 | ALDH1A1 (0.43) | KMT2AALDH1A1MEN1HTTGAA | |
| SCHEMBL1156776 | 0.84 | LMNA (0.45) | KMT2AALDH1A1MEN1HTTLMNA | |
| SCHEMBL1580924 | 0.83 | LMNA (0.49) | KMT2AALDH1A1MEN1HTTLMNA | |
| Hydrochloric Acid SCHEMBL1156936 | 0.82 | LMNA (0.48) | KMT2AALDH1A1MEN1HTTLMNA | |
| SCHEMBL1156773 | 0.80 | ALDH1A1 (0.44) | KMT2AALDH1A1MEN1HTTLMNA | |
| SCHEMBL1157066 | 0.80 | ALDH1A1 (0.47) | KMT2AALDH1A1MEN1HTTLMNA | |
| SCHEMBL1156393 | 0.79 | PPME1 (0.40) | — | |
| SCHEMBL1156641 | 0.75 | AKR1C3 (0.45) | KMT2AALDH1A1MEN1LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048909-B2 | Proton pump inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-01 | — | — | US | disclosed |
| EP-2336107-A2 | Proton pump inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
| US-20110028476-A1 | PROTON PUMP INHIBITORS | KAJINO MASAHIRO | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028476-A1 | PROTON PUMP INHIBITORS | HRH2, HRH4, CYP2C19 | KMT2A 2255/4885ALDH1A1 2505/4885MEN1 2402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.